Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of CoronaVac Booster in Adults
NCT05156632Phase 3Withdrawn
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Feb 2023
- Primary completion
- Feb 2023
- Modality
- Whole Inactivated Vaccines
01
Overview
Phase 3, randomised, double-blind trial of coronavac in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Sinovac Biotech Ltd. Primary endpoint: COVID-19 incidence at 6 months. Planned start Feb 2023; status: withdrawn.
02
Drugs
coronavac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05156632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05156632.